GS-4182
Sponsors
Gilead Sciences Inc.
Conditions
HIV-1 Infection
Phase 2
An Operationally Seamless Phase 2/3, Randomized, Active Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination with GS-4182 Versus Biktarvy in Treatment Naive People with HIV-1
SuspendedCTIS2024-512505-66-00
Start: 2025-03-03Target: 186Updated: 2025-10-29
An Operationally Seamless Phase 2/3, Randomized, Active -Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1
Not yet recruitingCTIS2024-511054-50-00
Target: 35Updated: 2025-04-02